CVR: 44860627
Secondary names: TUSTAR ApS
DKK -961,543
Gross profit
Net result: DKK -880,765
Afyx Capital ApS, Hannibal Innovation ApS
CVR · view ownership and management
Director registered: Hamed Mozaffari Brodersen
CVR · 29/05/2024
View the full event history
BARKA Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hamed Mozaffari Brodersen. The company is owned by Afyx Capital ApS and Hannibal Innovation ApS. In 2025, the company reported a gross profit of DKK -961,543 and a net result of DKK -880,765. Equity in the 2025 report amounted to DKK -605,209.
Selskabets formål er at drive forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler, og dermed beslægtet virksomhed efter ledelsens skøn
Source: annual reports filed with the Danish Business Authority.
Compared to 1.041 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreBARKA Therapeutics ApS was founded on 29 May 2024.
BARKA Therapeutics ApS is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721000).
BARKA Therapeutics ApS is owned by Afyx Capital ApS and Hannibal Innovation ApS.
In 2025, BARKA Therapeutics ApS reported a gross profit of DKK -961,543.
The management of BARKA Therapeutics ApS consists of Hamed Mozaffari Brodersen.
BARKA Therapeutics ApS is located at c/o Afyx Therapeutics ApS, Slotsmarken 11, 2970 Hørsholm.
Claim this page to add your logo and social links. Free to get started.
BARKA Therapeutics ApS has published its annual report for 2025. Revenue came to DKK 0, and the net result was DKK -880,765.
BARKA Therapeutics ApS has published its interim report for the period May 29, 2024 – December 31, 2024.
As of May 29, 2024, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of BARKA Therapeutics ApS.
As of May 29, 2024, Ole Baadsgaard has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Karin Absalonsen has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Claus Juan Møller-San Pedro has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Hamed Mozaffari Brodersen has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Hamed Mozaffari Brodersen is registered as director of BARKA Therapeutics ApS.
As of May 29, 2024, Afyx Capital ApS is registered as an owner of BARKA Therapeutics ApS with an ownership share of 33%.
As of May 29, 2024, Hannibal Innovation ApS is registered as an owner of BARKA Therapeutics ApS with an ownership share of 66%.
BARKA Therapeutics ApS was founded on May 29, 2024.
Companies in the same industry and area
CVR 35388737
CVR 26206308
CVR 37053678
CVR 37726028
CVR 45089770
